Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Survodutide Cardiac Safety in Overweight/Obesity
NCT06200467Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2024
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of survodutide in obesity (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Time-matched QTcI change from baseline at 30 weeks. Started Mar 2024; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06200467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06200467.